Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lee W. Page is active.

Publication


Featured researches published by Lee W. Page.


Bioorganic & Medicinal Chemistry Letters | 2010

Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor.

Muna H. Abdi; Paul John Beswick; Andy Billinton; Laura J. Chambers; Andrew Charlton; Sue D. Collins; Katharine L. Collis; David Kenneth Dean; Elena Fonfria; Robert J. Gleave; Clarisse L. Lejeune; David G. Livermore; Stephen J. Medhurst; Anton D. Michel; Andrew P. Moses; Lee W. Page; Sadhana Patel; Shilina Roman; Stefan Senger; Brian P. Slingsby; Jon Graham Anthony Steadman; Alexander J. Stevens; Daryl Simon Walter

A computational lead-hopping exercise identified compound 4 as a structurally distinct P2X(7) receptor antagonist. Structure-activity relationships (SAR) of a series of pyroglutamic acid amide analogues of 4 were investigated and compound 31 was identified as a potent P2X(7) antagonist with excellent in vivo activity in animal models of pain, and a profile suitable for progression to clinical studies.


Bioorganic & Medicinal Chemistry Letters | 2010

Synthesis and evaluation of 3-amino-6-aryl-pyridazines as selective CB2 agonists for the treatment of inflammatory pain

Robert J. Gleave; Paul John Beswick; Andrew J. Brown; Gerard Martin Paul Giblin; Paul Goldsmith; Carl Haslam; William Leonard Mitchell; Neville Hubert Nicholson; Lee W. Page; Sadhana Patel; Susan Roomans; Brian P. Slingsby; Martin E. Swarbrick

A series of 3-amino-6-aryl-pyridazines have been identified as CB(2) agonists with high efficacy and selectivity against the CB(1) receptor. Details of the investigation of structure-activity relationships (SAR) are disclosed, which led to the identification of pyridazine analogue 35, a compound with high potency in an in vivo model of inflammatory pain.


Bioorganic & Medicinal Chemistry Letters | 2009

Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.

Martin E. Swarbrick; Paul John Beswick; Robert J. Gleave; Richard Howard Green; Sharon Bingham; C. Bountra; Malcolm Clive Carter; Laura J. Chambers; Iain P. Chessell; Nick M. Clayton; Sue D. Collins; John Andrew Corfield; C. David Hartley; Savvas Kleanthous; Paul F. Lambeth; Fiona S. Lucas; Neil Mathews; Alan Naylor; Lee W. Page; Jeremy John Payne; Neil Anthony Pegg; Helen Susanne Price; John Skidmore; Alexander J. Stevens; Richard Stocker; Sharon C. Stratton; Alastair J. Stuart; Joanne Wiseman

A novel series of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidine-based cyclooxygenase-2 (COX-2) inhibitors, which have a different arrangement of substituents compared to the more common 1,2-diarylheterocycle based molecules, have been discovered. For example, 2-(butyloxy)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine (47), a member of the 2-pyrimidinyl ether series, has been shown to be a potent and selective inhibitor with a favourable pharmacokinetic profile, high brain penetration and good efficacy in rat models of hypersensitivity.


Acta Crystallographica Section C-crystal Structure Communications | 2009

An unusual methylene aziridine refined in P2(1)/c and the nonstandard setting P2(1)/n.

George C. Feast; James Haestier; Lee W. Page; Jeremy Robertson; Amber L. Thompson; David J. Watkin

The unusual methylene aziridine 6-tert-butyl-3-oxa-2-thia-1-azabicyclo[5.1.0]oct-6-ene 2,2-dioxide, C(9)H(15)NO(3)S, was found to crystallize with two molecules in the asymmetric unit. The structure was solved in both the approximately orthogonal and the oblique settings of space group No. 14, viz. P2(1)/n and P2(1)/c, respectively. A comparison of these results clearly displayed an increase in the correlation between coordinates in the ac plane for the oblique cell. The increase in the corresponding covariances makes a significant contribution to the standard uncertainties of derived parameters, e.g. bond lengths. Since there is yet no CIF definition for the full variance-covariance matrix, there are clear advantages to reporting the structure in the nonstandard space-group setting.


Journal of Medicinal Chemistry | 2016

Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.

Alison Jo-Anne Woolford; Joseph E. Pero; Sridhar Aravapalli; Valerio Berdini; Joseph E. Coyle; Philip J. Day; Andrew M. Dodson; Pascal Grondin; Finn P. Holding; Lydia Y. W. Lee; Peng Li; Eric S. Manas; Joseph P. Marino; Agnes C. L. Martin; Brent W. Mccleland; Rachel McMenamin; Christopher W. Murray; Christopher E. Neipp; Lee W. Page; Vipulkumar Kantibhai Patel; Florent Potvain; Sharna J. Rich; Ralph A. Rivero; Kirsten S. Smith; Donald O. Somers; Lionel Trottet; Ranganadh Velagaleti; Glyn Williams; Ren Xie

Elevated levels of human lipoprotein-associated phospholipase A2 (Lp-PLA2) are associated with cardiovascular disease and dementia. A fragment screen was conducted against Lp-PLA2 in order to identify novel inhibitors. Multiple fragment hits were observed in different regions of the active site, including some hits that bound in a pocket created by movement of a protein side chain (approximately 13 Å from the catalytic residue Ser273). Using structure guided design, we optimized a fragment that bound in this pocket to generate a novel low nanomolar chemotype, which did not interact with the catalytic residues.


Bioorganic & Medicinal Chemistry Letters | 2009

2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.

Robert J. Gleave; Paul John Beswick; Andrew J. Brown; Gerard Martin Paul Giblin; Carl Haslam; David G. Livermore; Andrew P. Moses; Neville Hubert Nicholson; Lee W. Page; Brian P. Slingsby; Martin E. Swarbrick

2-Amino-5-aryl-pyridines, exemplified by compound 1, had been identified as a synthetically tractable series of CB(2) agonists from a high-throughput screen of the GlaxoSmithKline compound collection. Described herein are the results of an investigation of the structure-activity relationships (SAR) which led to the identification a number of potent and selective agonists.


Chemical Communications | 2010

The intramolecular amination of allenes.

George C. Feast; Lee W. Page; Jeremy Robertson


ACS Medicinal Chemistry Letters | 2015

Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors

Christopher W. Murray; Valerio Berdini; Ildiko Maria Buck; Maria E. Carr; Anne Cleasby; Joseph E. Coyle; Jayne Curry; James E. H. Day; Phillip J. Day; Keisha Hearn; Aman Iqbal; Lydia Y. W. Lee; Vanessa Martins; Paul N. Mortenson; Joanne M. Munck; Lee W. Page; Sahil Patel; Susan Roomans; Kirsten Smith; Emiliano Tamanini; Gordon Saxty


Archive | 2006

Pyridazine derivatives with antiinflammatory activity

Robert J. Gleave; William Leonard Mitchell; Lee W. Page; Martin Swarbrick


Tetrahedron Letters | 2010

The acid-mediated intramolecular 1,3-dipolar cycloaddition of derived 2-nitro-1,1-ethenediamines for the synthesis of novel fused bicyclic isoxazoles

Lee W. Page; Matthew Bailey; Paul John Beswick; Simon Frydrych; Robert J. Gleave

Collaboration


Dive into the Lee W. Page's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge